Table 1.
Clinical characteristics and hemodynamics of PH patients.
| Clinical characteristic | Value |
|---|---|
| Functional status, | |
| NYHA functional class II, III, IV (n) | 30, 51, 20 |
| 6MWD (predicted), m | 443 ± 142 (589 ± 102) |
| Dyspnoe score (Borg index) | 4 ± 2 |
| Diagnosis (n) | |
| Idiopathic PAH | 41 |
| Familial PAH | 9 |
| PAH associated with | |
| Systemic sclerosis | 27 |
| Portal hypertension | 1 |
| HIV | 2 |
| Chronic thromboembolic pulmonary hypertension | 21 |
| Treatment† (n) | |
| Bosentan | 17 |
| Bosentan + Sildenafil | 15 |
| Epoprostenol | 13 |
| Sildenafil | 7 |
| Epoprostenol + Sildenafil | 7 |
| Sitaxentan | 5 |
| Sildenafil + Sitaxentan | 4 |
| Treprostinil + Bosentan + Sildenafil | 3 |
| Epoprostenol + Sildenafil + Bosentan | 3 |
| Treprostinil + Sitaxentan | 2 |
| Calcium Antagonist | 2 |
| Bosentan + Epoprostenol | 2 |
| Treprostinil + Sildenafil | 1 |
| Hemodynamics | |
| Heart rate, beats/min | 79 ± 13 |
| Mean pulmonary artery pressure, mmHg | 46 ± 16 |
| Mean right atrial pressure, mmHg | 6 ± 4 |
| Pulmonary capillary wedge pressure, mmHg | 8 ± 4 |
| Pulmonary vascular resistance, dyn.s/cm5 | 632 ± 370 |
| Cardiac output, l/min | 5,5 ± 1,9 |
| Cardiac index, l/min/m2 | 3,0 ± 0,9 |
| Mixed venous O2 saturation, % | 67 ± 9 |
| Cardiopulmonary exercise testing* | |
| VO2,peak (ml/min) | 1039 ± 544 |
| VO2,peak-predicted (%) | 46.0 ± 20.7 |
*Data obtained in a subset of patients (n = 66). †Note that a considerable number of patients went through different regimens before study enrollment.
NYHA = New York Heart Association functional class; 6MWD = six minute walk distance.
Values are mean ± SD.